Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation

Not available.

[1]  O. Bernard,et al.  Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact , 2021, American journal of hematology.

[2]  Marcos González,et al.  6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival , 2020, British journal of haematology.

[3]  Sherine F. Elsawa,et al.  Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia , 2019, Oncotarget.

[4]  L. Trippa,et al.  Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Kyle,et al.  Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States , 2019, British journal of haematology.

[6]  J. Cerhan,et al.  Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma , 2018, Blood Cancer Journal.

[7]  M. Cazzola,et al.  MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4 , 2018, Haematologica.

[8]  S. Treon,et al.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[9]  S. Chevret,et al.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia , 2013, Haematologica.

[10]  R. Fonseca,et al.  Molecular pathogenesis of Waldenström’s macroglobulinemia , 2012, Haematologica.

[11]  J. Koshiol,et al.  Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. , 2010, Journal of the National Cancer Institute.

[12]  Victor R. Preedy,et al.  Overall Response Rate , 2010 .

[13]  M. Bernard,et al.  The Clinical Spectrum of IgM-Related Amyloidosis: A French Nationwide Retrospective Study of 72 Patients , 2008, Medicine.

[14]  J. Hernández-Rivas,et al.  6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis , 2007, British journal of haematology.

[15]  J. Crowley,et al.  Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). , 2001, Blood.

[16]  E. Hatzimichael,et al.  Serum levels of IL‐6 and its soluble receptor (sIL‐6R) in Waldenström's macroglobulinemia , 2001, European journal of haematology.

[17]  W. Vainchenker,et al.  Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.